Inflammatory Bowel Disease(IBD)Database

Not yet recruiting

• Conditions: Inflammatory Bowel Disease

• Registration Number: NCT01266538
• Lead Sponsor: Tel-Aviv Sourasky Medical Center

Brief Summary

This will be a comprehensive epidemiological, clinical, endoscopic and histological database for inflammatory bowel diseases patients in our medical center that will further provide clinical and basic investigations.

Detailed Description

Inflammatory bowel diseases (IBD), which include Crohn's disease (CD), ulcerative colitis (UC), undefined IBD and pouchitis (in patients who required IPAA for their colitis) affects about two million people in the world. At this time there is no definitive cure and current treatment is aimed at managing the symptoms and inflammation that accompany these diseases. These diseases are predominantly chronic, and patients may experience various gastrointestinal symptoms depending on the location, nature, and extent of their disease. Both genetic and environmental factors play etiological roles. The overall goal of our research is to understand the etiology and course of these diseases in order to prevent and to manage cases more effectively. In order to do so we are aiming at building a comprehensive database that will include detailed clinical data conjoined with dedicated research information and collection of biological specimens that will target the gut epithelium immune system, the microbiota and specific genetic risk factors.

Study Timeline

• Status Verified: 2010-12
• Study First Submitted: 2010-12-23
• Study First Submitted QC: 2010-12-23
• Last Update Submitted: 2010-12-23
• Study First Posted: 2010-12-24
• Last Update Posted: 2010-12-24
• Study Start: 2011-01
• Primary Completion: 2026-12
• Study Completion: 2026-12

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 2500

Inclusion Criteria

Diagnosis of IBD Regular treatment and follow up in Tel Aviv Sourasky medical center Fap (familial polyposis)patients after a large bowel resection, as controls Family members of IBD patients as controls Patients with Irritable Bowel Syndrome (IBS), as controls -

Exclusion Criteria

pregnancy age<18 years

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
flactuations in gastrointestinal inflammation	ongoing, up to 4 times a year

Secondary Outcome Measures

Name	Time	Method
development of IBD-related morbidity and complications over time	ongoing, up to 4 times a year

Trial Locations

Locations (1)

Tel Aviv Sourasky Medical Center; 🇮🇱 Tel Aviv, Israel